BridgeBio-Backed CoA Therapeutics Challenges Retrophin In Genetic Disorder PKAN
Executive Summary
Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic disorder PKAN during the first quarter of 2020.